JP2018530617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530617A5 JP2018530617A5 JP2018538935A JP2018538935A JP2018530617A5 JP 2018530617 A5 JP2018530617 A5 JP 2018530617A5 JP 2018538935 A JP2018538935 A JP 2018538935A JP 2018538935 A JP2018538935 A JP 2018538935A JP 2018530617 A5 JP2018530617 A5 JP 2018530617A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- independently selected
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518456.7 | 2015-10-19 | ||
| GBGB1518456.7A GB201518456D0 (en) | 2015-10-19 | 2015-10-19 | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
| PCT/EP2016/074662 WO2017067848A1 (en) | 2015-10-19 | 2016-10-14 | 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530617A JP2018530617A (ja) | 2018-10-18 |
| JP2018530617A5 true JP2018530617A5 (enExample) | 2019-11-21 |
Family
ID=55131239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538935A Ceased JP2018530617A (ja) | 2015-10-19 | 2016-10-14 | ＩＲＡＫ阻害剤としての６−［５−アミノ−６−（２−エトキシエトキシ）−イミダゾ［４，５−ｂ］ピリジン−３−イル］−ニコチノニトリル誘導体及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10508111B2 (enExample) |
| EP (1) | EP3365341B1 (enExample) |
| JP (1) | JP2018530617A (enExample) |
| KR (1) | KR20180064528A (enExample) |
| CN (1) | CN108137584A (enExample) |
| AR (1) | AR106384A1 (enExample) |
| AU (1) | AU2016343225A1 (enExample) |
| BR (1) | BR112018007392A2 (enExample) |
| CA (1) | CA3002255A1 (enExample) |
| CO (1) | CO2018004765A2 (enExample) |
| GB (1) | GB201518456D0 (enExample) |
| IL (1) | IL258707A (enExample) |
| MX (1) | MX2018004517A (enExample) |
| PH (1) | PH12018500827A1 (enExample) |
| RU (1) | RU2018117499A (enExample) |
| SG (1) | SG11201803095UA (enExample) |
| TW (1) | TW201718582A (enExample) |
| WO (1) | WO2017067848A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| GB201702603D0 (en) * | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| GB201904373D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY28506A1 (es) * | 2003-09-12 | 2005-04-29 | Basf Ag | 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales. |
| DK1704145T3 (da) * | 2004-01-12 | 2012-09-24 | Ym Biosciences Australia Pty | Selektive kinaseinhibitorer |
| JP5766820B2 (ja) * | 2011-02-09 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｐｉ３キナーゼ阻害剤としての複素環化合物 |
| KR20160092991A (ko) * | 2013-09-27 | 2016-08-05 | 님버스 아이리스 인코포레이티드 | Irak 억제제 및 이의 용도 |
| TW201609693A (zh) * | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
-
2015
- 2015-10-19 GB GBGB1518456.7A patent/GB201518456D0/en not_active Ceased
-
2016
- 2016-10-14 MX MX2018004517A patent/MX2018004517A/es unknown
- 2016-10-14 JP JP2018538935A patent/JP2018530617A/ja not_active Ceased
- 2016-10-14 RU RU2018117499A patent/RU2018117499A/ru not_active Application Discontinuation
- 2016-10-14 AU AU2016343225A patent/AU2016343225A1/en not_active Abandoned
- 2016-10-14 SG SG11201803095UA patent/SG11201803095UA/en unknown
- 2016-10-14 BR BR112018007392A patent/BR112018007392A2/pt not_active Application Discontinuation
- 2016-10-14 WO PCT/EP2016/074662 patent/WO2017067848A1/en not_active Ceased
- 2016-10-14 CN CN201680060910.6A patent/CN108137584A/zh active Pending
- 2016-10-14 EP EP16794525.2A patent/EP3365341B1/en active Active
- 2016-10-14 KR KR1020187013738A patent/KR20180064528A/ko not_active Withdrawn
- 2016-10-14 CA CA3002255A patent/CA3002255A1/en not_active Abandoned
- 2016-10-14 US US15/769,260 patent/US10508111B2/en not_active Expired - Fee Related
- 2016-10-17 AR ARP160103166A patent/AR106384A1/es unknown
- 2016-10-18 TW TW105133608A patent/TW201718582A/zh unknown
-
2018
- 2018-04-15 IL IL258707A patent/IL258707A/en unknown
- 2018-04-17 PH PH12018500827A patent/PH12018500827A1/en unknown
- 2018-05-03 CO CONC2018/0004765A patent/CO2018004765A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530617A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| RU2011108026A (ru) | Комбинированная терапия туберкулеза | |
| JP2014518266A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2018115191A5 (enExample) | ||
| JP2017531038A5 (enExample) | ||
| JP2013542247A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2017520613A5 (enExample) | ||
| JP2013519632A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2015509075A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| JP2017513917A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| JP2017533930A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| MX2013009709A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7. |